Marpai confirms Q2 2023 revenue guidance of $9.5M-$9.8M; expects EBITDA improvement

Marpai, Inc.

2023-Q2 EPS reported -$2.70 vs consensus -$1.31 ▼ miss (-106.8%)

Preliminary Q2 2023 revenue between $9.5M and $9.8M.
Expects sequential improvement in EBITDA and net income vs Q1 2023.
Progress on Maestro Health integration and cost-cutting cited for improved profitability.
Revenue roughly flat sequentially as previously anticipated.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Marpai, Inc. reported Q2 2023 results: revenue $9.5 million to $9.8 million. Guidance reaffirmed.

Period: Q2 2023
Revenue: $9.5 million to $9.8 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Marpai Confirms Revenue Guidance for Q2 2023 of $9.5 Million to $9.8 Million Company cites expected improvements in EBITDA NEW YORK—( BUSINESS WIRE )— Marpai, Inc .—June 29, 2023—("Marpai" or the "Company") (Nasdaq: MRAI), an AI-powered Third-Party Administrator (TPA) transforming self-funded employer health plans, confirmed its revenue guidance for Q2 2023 as between $9.5 million to $9.8 million.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Marpai, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-030886

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.